Bristol-Myers bumps off chief scientist in another big shakeup, bringing in Celgene and Novartis execs
Just 2 years after Tom Lynch stepped from the board room to the top scientific position at Bristol-Myers Squibb, he’s out.
The pharma giant reported …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
